Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2025 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2025 Earnings Call Transcript May 13, 2025Adaptimmune Therapeutics plc beats earnings expectations.
Posts Tagged ‘NASDAQ:ADAP’
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call. As a reminder, all participants are in a listen-only mode.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2024 Earnings Call Transcript
Operator: Hello and welcome to the Adaptimmune Therapeutics Third Quarter 2024 Results Conference Call.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2024 Earnings Call Transcript
Operator: Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call. All participants will be in a listen-only mode.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
Operator: Hello and welcome to Adaptimmune's Fourth Quarter and Year-End Conference Call and Business Update. I will now turn the call over to Juli Miller.
15 Top Performing European Stocks So Far in 2024
In this piece, we will take a look at the 15 top performing European stocks so far in 2024.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune’s Q3 Financial and Business Update Conference Call.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to Adaptimmune’s Q2 Financial and Business Update Conference Call.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2023 Earnings Call Transcript
Juli Miller: Good morning, and welcome to Adaptimmune's conference call to discuss our first quarter 2023 financial results and business updates.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2022 Earnings Call Transcript
Operator: Welcome to Adaptimmune and TCR2 joint webcast to discuss their strategic combination announced earlier this morning.
5 High Growth UK Stocks to Buy
Adaptimmune Therapeutics plc (NASDAQ:ADAP) is a biotechnology firm that develops tumor and cancer treatments.
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q3 2022 Earnings Call Transcript
Juli Miller: Good morning and welcome to Adaptimmune's conference call to discuss our third quarter 2022 financial results and business update.
Is ADAP A Good Stock To Buy Now?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Have Never Been This Bullish On Adaptimmune Therapeutics plc (ADAP)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Should You Buy Adaptimmune Therapeutics plc (ADAP)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy...
Is Adaptimmune Therapeutics plc (ADAP) Going To Burn These Hedge Funds ?
Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren't very good.
Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns.
Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great...
Hedge Fund and Insider Trading News: Anthony Scaramucci, Solus Alternative Asset Management, Adaptimmune Therapeutics PLC (ADAP), Motorola Solutions Inc (MSI), BK Technologies Inc (BKTI), and More
Anthony Scaramucci, founder of hedge fund SkyBridge Capital and the Trump administration's White House communications director for 10 days in 2017, is selling his Southampton, ...
Hedge Fund and Insider Trading News: Elliott Management, HG Vora Capital Management, OncoCyte Corp (OCX), Solaredge Technologies Inc (SEDG), Autodesk, Inc. (ADSK), and More
Commvault, a provider of backup and recovery software, will soon find itself in a proxy battle with Elliott Management.
13D Filing: OrbiMed Advisors and Adaptimmune Therapeutics PLC – ADR (ADAP)
Please follow OrbiMed Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about OrbiMed Advisors or update its stock holdings...
Market Movers Today: Solid Biosciences Inc (SLDB), Adaptimmune Therapeutics PLC – ADR (ADAP), Snap Inc (SNAP), Image Sensing Systems, Inc. (ISNS), and More
What happened: Shares of Solid Biosciences Inc.
13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC – ADR (ADAP)
Please follow Matrix Capital Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Matrix Capital Management or update...
KBR Inc. (KBR), Autohome Inc. (ADR) (ATHM) & More: Here’s Why These Stocks Are on Investors’ Radars
The US stock market slumped on Thursday, with the Dow Jones and S&P 500 down by around 0.5%.
Here’s What We Want To See From Adaptimmune Therapeutics PLC – ADR (ADAP)
Earlier in August, we highlighted Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) as being a company to watch going forward, with a specific focus on the company’s pipeline...
Samuel Isaly’s New Healthcare Positions: Community Health Systems (CYH), Glaukos Corp (GKOS), More
Samuel Isaly’s OrbiMed Advisors is a healthcare fund with $15 billion worth of assets under management.
